Page 90 - Sohini Das

PM Modi meet with CMs to kickstart mega Covid-19 vaccination drive

The government is in the final stages of due diligence to ink a supply deal with Serum Institute of India and Bharat Biotech, which have got approval for emergency use of their vaccines

Serum Institute may supply around 400 million more doses to Gavi-Covax

Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose

Airlines get ready for Covid-19 vaccine journey ahead of inoculation drive

Government has asked airlines to get ready to transport 30 tonnes of vaccines immediately

Covid-19 vaccine: Bharat Biotech completes recruitment for phase 3 trials

More than 5,000 people have been given both shots of the vaccine; efficacy data around March

Bharat Biotech vaccine may cost less than Serum's; govt working on pricing

The final contract is expected to be signed soon

Domestic drug market bounces back in Dec, ends CY20 with 3.1% growth

Clocks 8.5% growth in December, up sharply from November's 1% due to revival in volume growth

Next big bet: Experts bullish on Bharat Biotech's upcoming nasal vaccine

Bharat Biotech is currently working on two intra-nasal vaccines

Vaccine firms Bharat Biotech, Serum Institute patch up after war of words

Adar Poonawalla and Krishna Ella issue joint statement saying they would work together to roll out Covid-19 vaccine

Govt clears air on Bharat Biotech's vaccine, says relied on safety data

Minutes of expert panel meeting made public

Bharat Biotech chief takes on Serum Institute in Covid-19 vaccine war

Krishna Ella turns the tables on critics, questions approval granted to Oxford-Astra vaccine

Covishield to cost Rs 200/dose for first 100 mn doses to govt: Serum CEO

MRP for private market Rs 1,000/ dose; current licence does not allow export or sale in private market

Serum, Bharat Biotech vaccines get restricted use approval from DCGI

While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India

A jab at risk: Serum's quest to lead the world in Covid-19 vaccine race

It took a chance by ramping up capacity on vaccines when they were yet to be approved and is set to emerge a global winner

Controversy around Bharat Biotech's Covaxin approval without efficacy data

Bharat Biotech's Covaxin is based on a whole inactivated virus platform, an old technology which is used to make vaccines given to infants

Pharma exports likely to get a boost on coronavirus vaccine shots

However, he said that many countries, especially the European Union, are likely to step up production and increase their portfolios in an attempt to reduce import reliability.

Covishield moves closer to roll-out; SII gets in-principle nod from panel

India would need 30 million doses in the first phase when it vaccinates the essential services workers including health care professionals, municipal and police staff, etc

Serum Institute gets SEC thumbs up; Bharat Biotech proposal being discussed

US giant Pfizer did not come to present its case on Friday before the Subject Expert Committee

Serum Institute to seek nod for two full-dose regimen of Covishield

Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen

State governments may use bank guarantees to buy Covid-19 vaccines

Advice comes from Centre; some states begin talks with pharma firms

Vial, syringe makers push the pedal as Covid-19 vaccine roll-out nears

Most firms plan to increase capacity to meet fresh orders